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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.023Primary clear-cell adenocarcinoma of the urethra, a rare tumor that histomorphologically resembles
clear-cell carcinoma of the female genital tract, occurs predominantly in women and is associated with a
relatively poor prognosis. The histogenesis of this rare urethral neoplasm has not been completely
resolved, but it is thought to arise from either müllerian rests or metaplastic urothelium. Herein, we
present comprehensive surgical pathological and cytopathological ﬁndings from a patient with primary
urethral clear-cell adenocarcinoma and describe next-generation sequencing results for this patient’s
unique tumordthe ﬁrst such reported characterization of molecular aberrations in urethral clear-cell
adenocarcinoma at the transcriptomic and genomic levels. Transcriptome analysis revealed novel gene
fusion candidates, including ANKRD28-FNDC3B. Whole-exome analysis demonstrated focal copy number
loss at the SMAD4 and ARID2 loci and 38 somatic mutations, including a truncating mutation in ATM and
a novel nonsynonymous mutation in ALK. (Am J Pathol 2014, 184: 584e591; http://dx.doi.org/
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Disclosures: None declared.Primary carcinomas of the urethra are rare and, unlike most
other genitourinary malignancies, occur more commonly in
women than men.1 In women, squamous cell carcinoma
constitutes the vast majority of urethral carcinomas (approxi-
mately 70%), whereas conventional urothelial (transitional
cell) carcinoma and conventional adenocarcinoma account for
another 20% and 10%, respectively. There is a striking
anatomical distribution of these tumors: distal urethral carci-
nomas are predominantly squamous cell type, whereas prox-
imal urethral carcinomas are more often urothelial or
adenocarcinoma type. Compared with other urinary tract ma-
lignancies, the prognosis for urethral carcinoma is poor, and
patients often present with metastatic disease. The two prin-
cipal prognostic factors for urethral carcinoma are pathological
stage and tumor location, with a tendency for distal tumors (ie,
squamous cell carcinoma) to have a better prognosis than
proximal tumors (ie, urothelial carcinoma or adenocarcinoma).stigative Pathology.
.Although rare variants have been reported, primary urethral
adenocarcinoma generally shows either columnar/mucinous or
clear-cell histomorphological features.2 Columnar/mucinous
adenocarcinoma resembles well-differentiated colonic or
endocervical adenocarcinoma, whereas clear-cell adenocarci-
noma is similar to clear-cell carcinoma of the female genital
tract. In their seminal report, Oliva and Young3 described the
Urethral Clear-Cell Adenocarcinomaclinicopathological characteristics of a large cohort of primary
urethral clear-cell adenocarcinomas. These tumors showed a
marked sex predilection, with 18 cases in women compared
with only 1 case in a man; in addition, most cases apparently
arose within abnormally dilated periurethral structuresdso-
called urethral diverticula. Histomorphologically, these tumors
displayed tubulocystic, papillary, and/or solid architecture and
were composed of cells with clear cytoplasm, conspicuous
nuclear atypia, and numerous mitotic ﬁgures.
The histogenesis of primary urethral clear-cell adenocarci-
noma has not been conclusively determined. Although it was
initially thought to arise from mesonephric remnants, the
current hypothesis is that clear-cell adenocarcinoma derives
from metaplastic urothelium or müllerian rests.1,3e5 Alterna-
tive, but less widely accepted, theories include that the tumor
originates from the periurethral (Skene’s) glands or results
from malignant transformation of nephrogenic adenoma.6e8
The immunophenotype of this tumor reﬂects its histogenetic
uncertainty.2e4,7,9e13 Tumor cells usually express PAX8,
cytokeratin (CK) 7, a-methylacyl-CoA racemase, HNF-1b,
and high molecular weight cytokeratin (CK34bE12) proteins;
there is often nuclear accumulation of p53; and theKi-67 index
is generally high (>25%). Tumor cells also show variable
expression of CA-125 and CK20 but are routinely negative for
prostate-speciﬁc antigen, estrogen receptor (ER), progesterone
receptor (PR), and p63 protein expression. Although Sung
et al5 recently demonstrated frequent copy number gain of
chromosomes 3, 7, and 17, similar to conventional urothelial
carcinoma, by ﬂuorescent in situ hybridization (FISH) in pri-
mary urethral clear-cell adenocarcinoma, little else is known
about its molecular oncogenesis.
Herein, we present a patient with primary urethral clear-
cell adenocarcinoma, detailing the relevant surgical patho-
logical and cytopathological ﬁndings. We also describe
next-generation sequencing results for this patient’s tumor
(the ﬁrst such analysis of this type for primary urethral clear-
cell adenocarcinoma), including several novel gene fusion
candidates, copy number loss at the SMAD4 and ARID2
loci, and somatic mutations in ATM and ALK.Materials and Methods
This study was approved by the University of Michigan
(Ann Arbor) Health Sciences Institutional Review Board.Immunohistochemistry
Immunohistochemistry (IHC) was performed by the Depart-
ment of Pathology at the University of Michigan Health
System using a BenchMark ULTRA automated stainer and the
ultraView Universal DAB Detection Kit (Ventana Medical
Systems, Oro Valley, AZ). The following primary antibodies
were used: PAX8 (predilute; Cell Marque, Rocklin, CA), CK7
and CK20 (1:200; Cell Marque), and ER, PR, p63, and p53
(predilute; Ventana Medical Systems).The American Journal of Pathology - ajp.amjpathol.orgSequencing and Mutation Analysis
Next-generation sequencing, including transcriptome, copy
number, mutation, and gene fusion analysis, was performed
as described previously.14e17 Whole-exome and tran-
scriptome sequencing was performed on a HiSeq 2000
(Illumina, San Diego, CA), and the resulting FASTQ
sequence ﬁles were processed through in-house pipelines.
For whole-exome sequencing, Novoalign Multithreaded
software version 2.08.02 (Novocraft Technologies, Selangor,
Malaysia) was used to align the sequencing reads to the
human reference genome build (hg19/GRCh37). Mutation
analysis was performed using VarScan 2 software version
2.3.2 (Washington University, St. Louis, MO),18 and pileup
ﬁles were produced by the SAMtools mpileup program.19
Indel analysis was performed using Pindel, version 0.2.4
(Washington University),20 and potential indel candidates
were evaluated manually. Detected variants were function-
ally annotated using ANNOVAR.21 For paired-end tran-
scriptome sequencing, reads were aligned using Tophat2
software version 2.0.4 (University of Maryland, College
Park, MD),22 which internally deploys the ultrafast short read
alignment algorithm Bowtie, version 0.12.8.23 Junction reads
supporting the fusion candidates were re-aligned with the
BLAT alignment tool (UCSC Genome Bioinformatics,
http://genome.ucsc.edu/cgi-bin/hgBlat, last accessed October
11, 2013) to conﬁrm the predicted fusion breakpoint, and a
full-length sequence of a fusion gene was constructed and
evaluated for potential open reading frames (ORFs) using
ORF Finder (National Center for Biotechnology Information,
http://www.ncbi.nlm.nih.gov/gorf/gorf.html, last accessed
October 11, 2013). Potential gene fusions with robust ORFs
were explored using the Simple Modular Architecture
Research Tool (http://smart.embl-heidelberg.de, last
accessed October 11, 2013) to examine the gain or loss of
known functional domains in the predicted fusion products.
Validation of Mutations and Fusions
For ATM somatic mutation validation, ATM exon 30 was PCR
ampliﬁed from genomic DNA with sequence-speciﬁc primers
(forward, 50-M13-TGGCATATAAGAATTAGAGATGCT-
GAA-30; and reverse, 50-TAACGTTGCGAACTGCTATCC-
30) and HotStart Taq DNA polymerase (Qiagen, Venlo, The
Netherlands). The PCR product was puriﬁed with ExoSap-IT
(Affymetrix, Santa Clara, CA) and subjected to Sanger
sequencing at the University of Michigan DNA Sequencing
Core using the M13 forward primer. Chromatograms were
analyzed with Sequencher software version 4.5 (Gene Codes,
Ann Arbor, MI).
For ANKRD28-FNDC3B gene fusion validation, total RNA
was isolated from formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissue samples using the miRNeasy FFPE Kit (Qiagen) and
reverse transcribed using Superscript III (Life Technologies,
Carlsbad, CA). PCRs were performed on a StepOne Real-
Time PCR System (Life Technologies) with SYBR Green585
Mehra et aldye and sequence-speciﬁc primers: ANKRD28-FNDC3B gene
fusion transcript (forward, 50-AACGGAGATCCTGATGAA-
GTTCG-30; and reverse, 50-TAACACTCAGGAGACTGG-
GGT-30) and GAPDH internal control (forward, 50-GT-
CTCCTCTGACTTCAACAGCG-30; and reverse, 50-ACCA-
CCCTGTTGCTGTAGCCAA-30).
Results
Clinical History, Presentation, and Initial Work-Up
The patient is a 56-year-old African American woman with
hepatitis C and uterine leiomyomata status post-hysterec-
tomy (20 years prior), who presented for evaluation of
abdominal pain and gross hematuria. In the patient’s own
words, her mother “nearly miscarried me twice in 1955, was
hospitalized and treated with estrogens, possibly DES.” From
approximately 1940 to 1970, diethylstilbestrol (DES) was
administered to pregnant women to reduce the risk of preg-
nancy complications and losses. In 1971, DES was shown to
cause a clear-cell vaginal tumor in women exposed to this
drug in utero. The US Food and Drug Administration sub-
sequently banned the use of DES in pregnant women.
Eight years before the patient’s presentation with hema-
turia, she had undergone bilateral salpingo-oophorectomy,
which demonstrated a left ovarian serous cystadenoma and a
right ovarian ﬁbroma, but no ovarian cancer. On the most
recent clinical evaluation, the patient was initially treated
with antibiotics for a presumed urinary tract infection,
without resolution of her symptoms. Follow-up studies
demonstrated urinary retention, bladder atony, and right-
sided hydronephrosis; urine cytological results were positive
for atypical cells, which was interpreted as consistent with
carcinoma, and reﬂex FISH testing with UroVysion showed
a few cells with variable aneuploidy. The patient was sub-
sequently referred for cystoscopic evaluation of a possible
bladder tumor.
Cystoscopic Findings and TUR
On cystoscopy, a 2.5-cm sessile lesion of the posterior bladder
wall was identiﬁed and completely resected. A separate large
mass, involving approximately 60% of the urethra and
apparently arising from within a diverticulum in the mid
posterior urethral wall, was discovered and partially resected.
Microscopic evaluation of the transurethral resection (TUR)
specimens revealed fragments of tumor with predominantly
papillary architecture (Figure 1A) and invasion into the lamina
propria of the urethra. Separate fragments of partially denuded,
reactive urothelium were identiﬁed, without evidence of uro-
thelial dysplasia or conventional urothelial carcinoma. Tumor
cells were medium sized, with distinct cell borders and vacu-
olated, clear cytoplasm; nuclei were basally located, medium
sized, pleomorphic, and hyperchromatic, with irregular nu-
clear membranes, but without prominent nucleoli (Figure 1B).
IHC demonstrated that the tumor cells diffusely and strongly586expressed PAX8 and CK7 (Figure 1, C and D) but were
negative for CK20, ER, PR, p53, and p63 protein expression
(data not shown). The histomorphological features and
immunophenotype were consistent with clear-cell adenocar-
cinoma. Repeat cystoscopy demonstrated residual tumor in the
bladder and urethra, and restaging TUR showed muscle-
invasive clear-cell adenocarcinoma with extension into the
bladder neck.
Urine Cytopathological Findings
Concomitant with repeat cystoscopic examination, voided
urine was obtained for cytopathological analysis; a ThinPrep
slide (Hologic, Bedford, MA) was prepared and Papanicolaou
stained.Microscopic examination revealed a cellular specimen
composed predominantly of cohesive clusters of epithelial
cells exhibiting overlapping nuclei with moderate to severe
nuclear pleomorphism (Figure 2A). In areas, pleomorphic
naked nuclei, singly and in loosely cohesive clusters, were also
present (Figure 2B). The nuclei exhibited a delicate, vesicular
to ﬁnely granular chromatin texture, and prominent nucleoli
were occasionally encountered. Associated with some of the
epithelial cell clusters, pseudohyphae and spore forms,
consistent with Candida organisms, were visualized
(Figure 2C). A cell block was prepared after pelleting the
cellular material in the residual sample. H&E-stained sections,
prepared from the cell block, revealed cohesive clusters of
polygonal epithelial cells exhibiting vacuolated, clear cyto-
plasm (Figure 2D). Based on the constellation of ﬁndings, a
diagnosis of clear-cell adenocarcinoma was conﬁrmed.
Surgical and Pathological Findings following Anterior
Pelvic Exenteration
Postcystoscopy magnetic resonance imaging of the abdomen
and pelvis showed irregular posterior bladder wall thick-
ening, from the level of the ureterovesical junction to the
bladder neck and into the proximal urethra, consistent with
postsurgical changes and probable residual tumor; limited
separation of residual tumor from the anterior vaginal wall
and bilateral pelvic lymphadenopathy were noted. A ques-
tionable 3-mm right upper lobe lung nodule was identiﬁed by
computed tomography of the chest, but no other evidence of
possible distant metastasis was detected. Overall, the cysto-
scopic, pathological, and radiological ﬁndings were consis-
tent with a muscle-invasive primary urethral clear-cell
adenocarcinoma with bladder neck involvement and regional
lymph node metastasis. Given her pelvic pain, severe urinary
symptoms, and uncertain response to systemic therapy, the
patient elected to undergo anterior pelvic exenteration and
bilateral pelvic lymph node dissection. Surgical pathological
analysis of the resection specimen revealed a primary urethral
clear-cell adenocarcinoma in the posterior wall of the prox-
imal urethra, which grossly invaded the periurethral muscle
into the periurethral and anterior vaginal soft tissue. The mass
also extended superiorly through the bladder neck into theajp.amjpathol.org - The American Journal of Pathology
Figure 2 Cytomorphological ﬁndings of a voided urine specimen in a
case of primary urethral clear-cell adenocarcinoma. AeC: Papanicolaou-
stained ThinPrep slides. A voided urine specimen contained cohesive,
three-dimensional clusters of epithelial cells with moderate to severe nu-
clear pleomorphism (A); pleomorphic, naked nuclei with delicate, ﬁnely
granular chromatin texture and occasionally prominent nucleoli (B); and
fungal spore forms and pseudohyphae, consistent with Candida organisms,
intimately associated with elongated epithelial cell clusters (C). D: A cell
block section demonstrated clusters of polygonal epithelial cells with clear
cytoplasm (H&E stain). Original magniﬁcation: 600 (AeC); 400 (D).
Figure 1 Histomorphological features and immunophenotype of a case
of primary urethral clear-cell adenocarcinoma. A and B: H&E and IHC
staining for CK7 (C) and PAX8 (D). A: The tumor showed a predominantly
papillary architecture with ﬁbrovascular septae and cores. B: Tumor cells
had vacuolated, clear cytoplasm and basally located pleomorphic nuclei
without prominent nucleoli. IHC demonstrated that tumor cells diffusely
and strongly expressed CK7 in a membranous pattern (C) and PAX8 in a
nuclear manner (D). Original magniﬁcation: 100 (A); 400 (BeD).
Urethral Clear-Cell Adenocarcinomabladder trigone, with invasion of the bladder wall muscle and
extension into the perivesicular adipose tissue. The soft tissue
resection margin was negative for carcinoma. Five of eight
pelvic lymph nodes were involved by metastatic clear-cell
adenocarcinoma. Taken together, the pathological staging of
our patient’s tumor was pT4N2, which corresponds to clin-
ical stage IV.24
Next-Generation Sequencing
Representative samples from FFPE tissue were selected for
next-generation sequencing. Copy number analysis revealed
several areas of copy number gain in tumor cells, including a
region of 7q11.21 containing TMEM248, SBDS, and TYW1
(log2 ratioZ 1.25); a region of 8q13.2 containing CPA6 and
PREX2 (log2 ratio Z 1.13); a region of 8q21.3 containing
RIPK2, OSGIN2, DECR1, and CALB1 (log2 ratioZ 1.10 to
1.51); a region of 20q13.33 containing SS18L1 and GTPBP5
(log2 ratioZ 1.29); and a region of 22q13.2 containing TEF,
TOB2, PHF5A, ACO2, POLR3H, and PMM1 (log2
ratio Z 1.32 to 2.08) (Figure 3A and Supplemental Table
S1). In addition, there was copy number loss of a region of
12q12 containing ARID2 (log2 ratioZ 1.41) and an area of
focal copy number loss on 18q21.2 containing SMAD4 (log2
ratio Z 0.98) (Figure 3, A and F).
Mutation analysis revealed 38 somatic point mutations,
including a nonsense mutation in ATM and a novel non-
synonymous mutation of unknown signiﬁcance in ALK
(Supplemental Tables S2 and S3). A cytosine to thymine
transition in exon 30 ofATM generates a premature stop codon
at amino acid position 1537; the predicted truncated ATM
protein lacks the critical C-terminal FAT and phosphatidyli-
nositol 3-kinase catalytic (PI3KC) domains (Figure 3B). ThisThe American Journal of Pathology - ajp.amjpathol.orgsomatic mutation in ATM was independently validated by
Sanger sequencing (Figure 3C). In the ALK gene, a thymine to
guanine transversion in exon 19 results in substitution of
proline for threonine at amino acid position 1026; this amino
acid change occurs N-terminal to the ALK tyrosine kinase
domain, in a region without well-characterized functional
domains. Finally, a single-nucleotide somatic insertion of
thymine in exon 10 ofATR results in a premature stop codon at
amino acid position 775 and, similar to the ATM nonsense
mutation, yields a truncated ATR protein without the FAT or
PI3KC domains; this ATR indel, however, could not be inde-
pendently validated by Sanger sequencing.
Transcriptome analysis identiﬁed 104 gene fusion candidates
(Supplemental Table S4), ﬁve of which were considered true-
positive candidates by subsequent manual curation:
ANKRD28-FNDC3B, RIPK2-OSGIN2, PDLIM1-LOC728558,
HMGA2-EML5, and RB1-SLC15A2 (Supplemental Table S4).
The ANKRD28-FNDC3B gene fusion results from an intra-
chromosomal rearrangement of chromosome 3, which joins
exon 2 of ANKRD28 to exon 4 of FNDC3B. The predicted
fusion protein contains most of the C-terminal portion of
FNDC3B, with nine ﬁbronectin type III domains and a single
transmembrane domain (Figure 3D). ThisANKRD28-FNDC3B
fusion transcript was independently validated by quantitative
PCR analysis (Figure 3E). The RIPK2-OSGIN2 gene fusion is
found in a region of copy number gain; it results from an
intrachromosomal rearrangement of chromosome 8, which
joins the last ﬁve exons of RIPK2 to the 30 untranslated region
of OSGIN2. The PDLIM1-LOC728558 gene fusion results
from an intrachromosomal rearrangement of chromosome 10,
which fuses exon 1 of PDLIM1 to an anti-sense, noncoding587
Figure 3 Next-generation sequencing of a case
of primary urethral clear-cell adenocarcinoma. A:
Copy number analysis demonstrated several re-
gions of copy number gain, as well as copy number
loss at 12q12 and 18q21.1, which contain the
ARID2 and SMAD4 loci (black arrowheads),
respectively: y axisZ log2 transformed tumor-to-
normal coverage ratio; and x axis Z genomic po-
sition, ascending from left to right (chromosome
number depicted above). B: Mutation analysis
revealed a truncating somatic mutation in ATM,
which results in a premature stop codon at amino
acid position 1537; the truncated ATM protein is
missing the FAT and PI3KC domains. C: Sanger
sequencing validation of this ATM somatic muta-
tion demonstrates a C-to-T nucleotide transition at
chr11:108163518 in the tumor sample but not
matched normal or control human genomic DNA.
D: A novel ANKRD28-FNDC3B gene fusion. Wild-
type ANKRD28 protein (ANKRD28-WT) contains
26 ankyrin repeats (ANK), and wild-type FNDC3B
protein (FNDC3B-WT) contains nine type ﬁbro-
nectin type III domains (FN3) and a single C-ter-
minal transmembrane domain (red box). The
ANKRD28-FNDC3B gene fusion transcript joins the
N-terminal portion of ANKRD28 and the C-terminal
portion of FNDC3B (black arrows), generating a
predicted translated peptide that contains only the
FN3 and transmembrane domains of FNDC3B
(ANKRD28-FNDC3B). E: Quantitative PCR validation
of this ANKRD28-FNDC3B gene fusion. All expres-
sion values are normalized to the internal control
GAPDH. F: High resolution of copy number losses at
ARID2 and SMAD4: y axis, log2 transformed tumor-
to-normal coverage ratio; and x axis, genomic
position (in Mb), with each point representing a
targeted exon and respective gene boundaries
being highlighted by red vertical lines.
Mehra et alRNA within the ENTPD1 locus. The HMGA2-EML5 gene
fusion results from a translocation between 12q14.3 and
14q31.3, which joins the ﬁrst three exons ofHMGA2 to the last
18 exons of EML5 (exons 27 to 44). The RB1-SLC15A2 gene
fusion results from a translocation between 3q13.33 and
13q14.2, which joins the ﬁrst 19 exons of RB1 to the last 13
exons of SLC15A2 (exons 10 to 22).
Clinical Follow-Up
A computed tomographic scan of the abdomen and thorax 2
months postoperatively showed no evidence of residual or
metastatic disease. Given the high pathological stage and
regional lymph node metastases, however, adjuvant radia-
tion and chemotherapy were recommended, and the patient588received two cycles of systemic cisplatin and approximately
48.2 Gy of radiation to the pelvis. At latest follow-up, 11
months after surgery, the patient was alive without evidence
of tumor recurrence.
Discussion
Primary urethral clear-cell adenocarcinoma is a rare,
aggressive tumor that poses a difﬁcult diagnostic challenge
for pathologists and a therapeutic question for urologists.
The differential diagnosis for urethral clear-cell lesions in-
cludes metastatic clear-cell carcinoma of the female genital
tract, urothelial carcinoma with clear-cell features or tubu-
locystic architecture, metastatic clear-cell renal cell carci-
noma (RCC), and nephrogenic adenoma.1 Distinguishingajp.amjpathol.org - The American Journal of Pathology
Urethral Clear-Cell Adenocarcinomaprimary urethral clear-cell adenocarcinoma from urothelial
carcinoma or metastatic clear-cell RCC is usually possible
based on histomorphological characteristics (eg, the pres-
ence of conventional urothelial carcinoma) and/or a limited
panel of IHC stains, including p63 (positive in urothelial
carcinoma) and CK7 (negative in clear-cell RCC). Although
nephrogenic adenoma can be a close histological and
immunophenotypic mimic of primary urethral clear-cell
adenocarcinoma,10,25 these two entities can usually be
distinguished on clinicoradiological grounds (eg, large mass
on cystoscopy or radiological evidence of regional or distant
metastasis) or by close pathological assessment.
Our patient’s case highlights the histogenetic uncertainty
of primary urethral clear-cell adenocarcinoma. The prevail-
ing theories suggest that these tumors arise from either
müllerian rests or metaplastic urothelium.1,3e5 Although our
patient’s tumor would be consistent with either of these
possibilities, because of its association with an apparent
urethral diverticulum, we favor that it most likely arose from
metaplastic urothelium. Urethral diverticula lead to urinary
stasis, which can result in recurrent urinary tract infections or
calculus formation.26 Similar to other areas of the urinary
tract, the resulting chronic irritation and inﬂammation can
predispose to malignant transformation. Although no
müllerian rests were identiﬁed in the TUR biopsy specimens
or main surgical specimen, the immunophenotype and loca-
tion of the tumor in the proximal posterior urethra suggest
that a müllerian origin cannot be completely excluded.
In addition to the surgical pathological ﬁndings of her
primary tumor, we have described cytopathological results
from a sample of our patient’s voided urine. The cytological
specimen demonstrated clusters of cohesive, vacuolated
epithelial cells with pleomorphic, vesicular nuclei and
prominent nucleoli, and the cell block specimen closely
resembled the tumor histomorphological characteristics in
the TUR (Figure 2). Although relatively few studies have
examined the cytopathological features of primary urethra
clear-cell adenocarcinoma, the reported cytomorphological
features are similar to our patient’s case, and cell block IHC
for PAX8, p63, CK7, CK20, p53, and Ki-67 may help to
discriminate between different urethral clear-cell le-
sions.13,27,28 These data suggest that, when sufﬁcient ma-
terials are not available by TUR biopsy specimen, urine
cytopathological analysis may be useful for the accurate
diagnosis of clear-cell adenocarcinoma.
The molecular oncogenesis of primary urethral clear-cell
adenocarcinoma is not well understood. To investigate
possible molecular mechanisms underlying tumorigenesis of
our patient’s unique cancer, we performed transcriptome,
copy number, and mutation analyses by next-generation
sequencingdthe ﬁrst such analysis for primary urethral
clear-cell adenocarcinoma. A recent report described FISH
analysis of primary urethral clear-cell adenocarcinoma and
showed frequent copy number gain of chromosomes 3, 7,
and 17, a pattern similar to conventional urothelial carci-
noma.5 In contrast, analysis of our patient’s tumor by next-The American Journal of Pathology - ajp.amjpathol.orggeneration sequencing demonstrated copy number gain of
chromosomes 7, 8, 20, and 22. The reason for this discor-
dance is unclear but may be the result of low sample size,
tumor heterogeneity, and/or differences in technique.
Interestingly, ampliﬁcation of chromosome 8 included the
PREX2 locus, a gene encoding a guanine nucleotide ex-
change factor whose overexpression is associated with in-
hibition of PTEN activity.29 Focal copy number loss at the
SMAD4 locus on chromosome 22 was also detected.
SMAD4 encodes a key intracellular protein in the bone
morphogenetic protein signaling pathway and functions as a
tumor suppressor in a variety of human cancers, most
notably pancreatic and colon cancers.30 SMAD4 loss of
heterozygosity is frequently observed in these cancer types,
and germ-line SMAD4 heterozygosity underlies juvenile
polyposis syndrome, a rare autosomal dominant disorder
characterized by hamartomatous polyps and tumors of the
gastrointestinal tract. Finally, we detected copy number loss
at the ARID2 locus on chromosome 12. ARID2 encodes a
DNA-binding protein involved in the speciﬁcity of chro-
matin remodeling by SWItch/sucrose nonfermentable (SWI/
SNF) complexes, and recurrent inactivating somatic muta-
tions in ARID2 have been detected in a range of human
cancers, including hepatocellular carcinoma, pancreatic
ductal adenocarcinoma, melanoma, and non-small cell lung
carcinoma.31e33
Mutation analysis revealed 38 somatic alterations in the
exome, including a truncating ATM mutation and a novel
nonsynonymous ALK mutation. The phosphoinositide 3-
kinase-related kinase subfamily member ATM is a protein
kinase with a well-recognized role in the cellular response to
DNA damage via activation of cell cycle checkpoints and acts
as a tumor suppressor in a variety of human cancers.34 The
nonsense ATM mutation results in a truncated ATM protein
(ie, without the FAT3 and PI3KC functional domains), which
leads to the disruption of the ATM-mediated DNA damage
response pathway. This is interesting in light of the lack of
nuclear p53 accumulation in our patient’s tumor, which is
otherwise a common IHC feature of primary urethral clear-cell
adenocarcinomas. Nuclear p53 expression in tumor cells
usually results from the accumulation of undegraded mutant
p53 after somatic alteration of TP53. Thus, the absence of
nuclear p53 accumulation in our patient’s tumor suggests an
intact TP53 gene, which is concordant with our next-
generation sequencing results. ATM and TP53 function
together in the DNA damage response pathway, and interest-
ingly, a negative correlation between ATM and TP53 muta-
tions has been reported in a large cohort of sequenced lung
adenocarcinomas.35 This suggests that mutation ofATM in our
patient’s tumormay be sufﬁcient for dysregulation of the DNA
damage response pathway. Finally, a nonsynonymous muta-
tion of unknown signiﬁcance was detected in the ligand-
binding domain of the orphan nuclear receptor transcription
factor NR5A2; interestingly, recent genome-wide association
studies have linked this gene locus to susceptibility for
pancreatic ductal adenocarcinoma.36589
Mehra et alTranscriptome analysis identiﬁed the novel gene fusion
candidate ANKRD28-FNDC3B. This gene fusion joins exon
2 of ANKRD28 to exon 4 of FNDC3B and generates an
essentially intact FNDC3B protein under aberrant tran-
scriptional control of the ANKRD28 regulatory regions
(Figure 3D). FNDC3B is present on chromosome 3q26,
which is frequently ampliﬁed in a diverse number of human
cancer types, and overexpression of FNDC3B has been
implicated in epithelial-to-mesenchymal transition and
activation of an array of cellular signaling pathways,
including retinoblastoma, phosphoinositide 3-kinase, and
mitogen-activated protein kinase/extracellular signale
regulated kinase.37 In hepatocellular carcinoma, for
example, FNDC3B ampliﬁcation and aberrant up-regulation
promote cellular proliferation via activation of the STAT3
signaling pathway.38
In summary, we have described the surgical pathological,
cytopathological, and molecular pathological ﬁndings from
a patient with primary urethral clear-cell adenocarcinoma.
Our patient’s tumor demonstrated many of the classic
clinical and histomorphological features of this rare,
aggressive cancer, and the urine cytopathological results
were concordant with emerging data in the scientiﬁc liter-
ature. Next-generation sequencing revealed a fount of novel
data about the possible molecular underpinnings of this
unique cancer type, including dysregulation of DNA dam-
age response (ATM) and chromatin remodeling (ARID2) and
changes in signaling pathways (PREX2, SMAD4, and
ANKRD28-FNDC3B). These molecular data highlight the
possibility of emerging clinical/therapeutic approaches to
rare tumors in the current era of personalized medicine and
provide exciting new opportunities to explore the molecular
oncogenesis of primary urethral clear-cell adenocarcinoma.
Follow-up studies with a larger cohort of tumors could
analyze molecular differences between clear-cell tumors of
the urinary and female genital tracts or investigate the as-of-
yet unresolved issue of the histogenesis of primary urethral
clear-cell adenocarcinoma.
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